H.C. Wainwright raised the firm’s price target on ArriVent Biopharma (AVBP) to $39 from $36 and keeps a Buy rating on the shares after the company entered into an exclusive license agreement with Lepu Biopharma. The firm says ArriVent’s portfolio continues to broaden with the MRG007 license.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVBP: